Nivolumab in pre-treated advanced non-small cell lung cancer: long term follow up data from the Dutch expanded access program and routine clinical care

BACKGROUND: For advanced non-small cell lung cancer anti-PD-1 treatment has become standard care in first and second line treatment in recent years. Because many of the clinical trials with anti-PD-1 drugs have only recently been completed, long term follow up data of patients treated with these age...

Descripción completa

Detalles Bibliográficos
Autores principales: Schouten, Robert D., Egberink, Lucie, Muller, Mirte, De Gooijer, Cornedine J., van Werkhoven, Erik, van den Heuvel, Michel M., Baas, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7653122/
https://www.ncbi.nlm.nih.gov/pubmed/33209597
http://dx.doi.org/10.21037/tlcr-19-698

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7653122/
https://www.ncbi.nlm.nih.gov/pubmed/33209597
http://dx.doi.org/10.21037/tlcr-19-698

Ejemplares similares